SF3A1 and neoplasm: Notably, strong growth inhibition was not detected in any non-cancerous cells (HCEC-1CT, HPPEC and Het1A) treated with the siRNA of nine RBPs (DHX8, EIF3G, RBM22, SF3A1, SNRPE, SUPT6H, U2AF1, UPF1, YBX1), suggesting that these RBPs possess a tumor-specific growth effect and are therefore attractive therapeutic targets in digestive cancer.